四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00460 四环医药

未开盘 09-28 16:08:28

0.720

+0.000

0.00%

最高0.735	最低0.710	成交量2,307万
今开0.725	昨收0.720	日振幅3.47%
总市值65.64亿	流通市值65.64亿	总股本91.16亿
成交额1,659万	换手率0.25%	流通股本91.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":0.72,"timestamp":1790582908003,"preClose":0.72,"halted":0,"volume":23073000,"delay":0,"changeRate":0,"floatShares":9116000000,"shares":9116000000,"eps":0.02303314949634418,"marketStatus":"未开盘","change":0,"latestTime":"09-28 16:08:28","open":0.725,"high":0.735,"low":0.71,"amount":16594232,"amplitude":0.034722,"askPrice":0.72,"askSize":4498000,"bidPrice":0.715,"bidSize":1113000,"shortable":3,"etf":0,"ttmEps":0.03914466218972606,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790645400000},"marketStatusCode":0,"adr":0,"listingDate":1288195200000,"exchange":"SEHK","adjPreClose":0.72,"dividendRate":0.015551,"openAndCloseTimeList":[[1790559000000,1790568000000],[1790571600000,1790582400000]],"volumeRatio":1.4513848902751194,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"2669170708","title":"【券商聚焦】广发证券首予四环医药（00460）买入评级 指医美与创新药进入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2669170708","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669170708?lang=zh_cn&edition=full","pubTime":"2026-09-23 14:04","pubTimestamp":1790143494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 广发证券发布研报指，四环医药 早期起家于心脑血管等仿制药业务，在医药集采期主动求变，积极向医美与创新药业务转型，2025年利润扭亏为盈，26H1归母净利达2.2亿元，进入业绩兑现阶段。渠道端，至26H1医美渠道覆盖终端机构超9000家，于行业承压下实现医美收入6.9亿元，同增18.5%，税前利润3.4亿元，同增10.9%。公司加速剥离非核心资产，创新药减亏与医美利润兑现进一步改善报表质量。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992305","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","MEDX","00460","159992","KCE","IBBQ","06978","01776"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669509139","title":"医美概念股多股上扬 三生制药（01530）涨5.71%、四环医药（00460）涨4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669509139","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669509139?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:09","pubTimestamp":1789956581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美概念股多股上扬，截至发稿，山东新华制药股份 涨10.81%，三生制药涨5.71%，四环医药涨4.17%，昊海生物科技涨3.82%，复星医药涨3.12%，现代牙科涨3.10%，时代天使涨2.25%。消息面上，国金证券表示，医美板块下游连锁景气回暖，上游平台化逻辑有望兑现，建议关注上游头部连锁化机构、需求扩容下具备强渠道能力的上游平台化标的。看好布局差异化赛道的上游医美产品厂商及满足医美新场景需求的下游医美机构。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992051","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","06826","BK1583","02196","BK1161","BK1587","00719","BK1600","03600","00460","BK1100","BK1191","01530","HK0000165453.HKD","06699","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169352351","title":"四环医药2026年中期营收11.61亿元，经营利润3.13亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1169352351","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169352351?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:57","pubTimestamp":1789549054,"startTime":"0","endTime":"0","summary":"四环医药发布2026年中期业绩。报告期内，公司实现营收11.61亿元，同比上升1.3%。本期毛利为6.82亿元，上年同期为7.57亿元，毛利率为58.7%。经营利润达3.13亿元，上年同期约2.64亿元，同比增长18.6%。经营活动现金流为-0.92亿元，上一年同期为-0.95亿元。分销开支2.17亿元，同比下降6.1%，占营收比例约18.71%；行政开支2.07亿元，同比下降2.2%；研发投入1.06亿元，同比下降30.9%，占营收比例约9.09%。公司医疗美容业务收入6.93亿元，同比增长18.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"四环医药2026年中期营收11.61亿元，经营利润3.13亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2664386607","title":"港股异动 | 四环医药(00460)午前涨近4% 轩竹生物与INNOBIC就吡洛西利于泰国市场达成商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386607","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664386607?lang=zh_cn&edition=full","pubTime":"2026-09-04 11:52","pubTimestamp":1788493955,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，四环医药午前涨近4%，截至发稿，涨3.92%，报0.795港元，成交额981.3万港元。Innobic(亚洲)将作为经销商，负责目标产品于目标区域的药品注册、本地市场营销及商业化运营。轩竹生物将按约定供货价格供应目标产品，以支持目标产品在目标区域的商业化活动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1515","02575","00460","BK1191","BK1593","KCAI","BK1600","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162680804","title":"四环医药(00460)子公司轩竹生物携手Innobic　独家推进吡洛西利片进入泰国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1162680804","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162680804?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:21","pubTimestamp":1788427316,"startTime":"0","endTime":"0","summary":"2026年9月3日，四环医药控股集团有限公司发布自愿公告称，其非全资附属公司轩竹生物科技股份有限公司已与泰国制药公司Innobic  Co., Ltd及ZaoAn International Trading Co., Ltd签署有关吡洛西利片的三方商业协议，协议有效期至2036年6月30日。根据协议，轩竹生物向Innobic（亚洲）及早安国际授予吡洛西利片在泰国市场的独家商业化权利，涵盖进口、推广、营销、要约销售、销售及经销等环节。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385197","title":"四环医药(00460.HK)授出合共1.16亿份股份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385197","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664385197?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:01","pubTimestamp":1788267673,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1600","BK1191","00460","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136509054","title":"四环医药8月股份变动月报表：回购1000万股纳入库存，总股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1136509054","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136509054?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:33","pubTimestamp":1788251596,"startTime":"0","endTime":"0","summary":"四环医药于2026年9月1日发布截至2026年8月31日的股份变动月报表。公告显示，公司法定/注册股本维持为100,000,000,000股，每股面值为港币0.01元，注册股本总额为港币1,000,000,000，与上月持平。2026年8月27日，公司以平均每股港币0.8111买回10,000,000股并将其转为库存股份，回购的股份暂未注销。本次交易完成后，公司流通股份减少至9,115,988,206股，库存股份增加至214,011,000股，总股份数仍为9,329,999,206股，股本总数维持不变。公告称，公司已符合香港联交所相关上市规则的公众持股量要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663012004","title":"四环医药(00460.HK)委任车雨轩为非执行董事 双轮驱动战略见效中期盈利翻倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2663012004","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663012004?lang=zh_cn&edition=full","pubTime":"2026-08-29 19:13","pubTimestamp":1788002032,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00460","BK1593","BK1600","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171641075","title":"四环医药(00460)回购1,000万股　耗资约811.1万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171641075","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171641075?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:06","pubTimestamp":1787832388,"startTime":"0","endTime":"0","summary":"2026年8月27日，四环医药控股集团有限公司公告称，公司已依据股东于2025年6月6日股东周年大会授权的一般回购授权，于2026年8月27日从公开市场回购股份。— 回购规模：共计回购股份10,000,000股，占公司已发行股份总数约0.1096%。公告同时披露，公司2026年上半年实现营收11.61亿元人民币，同比增长1.3%；净利润2.12亿元人民币，同比增长221%。董事会表示，当前股价未能充分反映公司内在价值，股份回购能够展现对未来业务发展的信心，并维护全体股东权益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662591706","title":"四环医药(00460.HK)8月27日耗资811.1万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662591706","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662591706?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:39","pubTimestamp":1787827197,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1600","00460","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167377227","title":"四环医药8月27日回购1000万股，耗资约811.10万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167377227","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167377227?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:36","pubTimestamp":1787826967,"startTime":"0","endTime":"0","summary":"四环医药于2026年8月27日发布翌日披露报表，公告公司当日通过香港联交所场内完成股份回购事宜，回购股份数量为1,000万股，约占回购前已发行股本的0.1096%。本次回购的最高回购价为每股0.82港元，最低回购价为每股0.77港元，合计支付约811.10万港元。根据公告，四环医药股份回购授权于2026年6月26日获股东大会批准，批准可回购股份总数为912,598,820股，此次回购后，已回购股份数为1,000万股，占授权总数的约0.1096%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"四环医药8月27日回购1000万股，耗资约811.10万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760937","title":"四环医药：缪瑰丽辞任执行董事 宋晓弥接任首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760937","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662760937?lang=zh_cn&edition=full","pubTime":"2026-08-26 13:51","pubTimestamp":1787723460,"startTime":"0","endTime":"0","summary":"8月26日，四环医药（00460）发布公告，公司执行董事、副行政总裁及首席财务官缪瑰丽因专注个人事业发展辞任。同时，公司委任车雨轩为非执行董事及董事会风险管理委员会委员，委任宋晓弥为首席财务官。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854445757.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854445757.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1600","00460","BK1515","BK1593","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662760602","title":"四环医药：上半年归母净利润2.25亿元 同比增119%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662760602","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662760602?lang=zh_cn&edition=full","pubTime":"2026-08-26 13:51","pubTimestamp":1787723460,"startTime":"0","endTime":"0","summary":"8月26日，四环医药（00460）发布2026年中期业绩，公司归母净利润达2.25亿元，同比增119%，主要由于医美业务收益增加。公司总收益约为11.61亿元，同比上升约1.3%。其中，医美业务的收益约为6.93亿元，同比上升约18.5%，主要得益于核心产品乐提葆?的稳定增长及再生类医美产品的持续放量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854446288.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854446288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662676239","title":"四环医药(00460)发布中期业绩 股东应占溢利2.25亿元 同比增加119% 持续锚定“医美+创新药”双轮驱动中长期发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2662676239","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662676239?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:31","pubTimestamp":1787718705,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药 发布截至2026年6月30日止6个月业绩，该集团期内取得总收益11.61亿元，同比增加1.3%;公司拥有人应占溢利2.25亿元，同比增加119%;每股基本盈利2.49分。公告称，收益的变化，主要来自医美及创新药业务驱动。期内，医美业务的收益约为人民币6.93亿元，同比上升约18.5%。医美业务保持稳健发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","00460","MEDX","06978","BK1515","LNGR","BK1191","BK1574","BK1593","BK1600","159992","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662764288","title":"四环医药：上半年拥有人应占溢利约2.2亿元 同比上升119%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662764288","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662764288?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:11","pubTimestamp":1787717487,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1593","00460","BK1515","BK1191","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158726883","title":"四环医药（00460）2026年中期业绩：医美与创新药双轮驱动，归母净利增逾一倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1158726883","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158726883?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:06","pubTimestamp":1787717203,"startTime":"0","endTime":"0","summary":"四环医药控股集团有限公司8月26日披露截至2026年6月30日止六个月未经审核之中期业绩。期内，公司实现多项核心财务指标增长，医美与创新药业务继续成为主要增长动力。其中，医美业务收入6.93亿元，同比增长18.5%；－ 董事会不派发2026年中期股息。公告显示，公司上半年继续聚焦“医美＋创新药”双轮驱动战略。公司表示，下半年将继续推进医美产品管线落地与全球布局，加快创新药商业化进程，并有序优化仿制药及非核心资产结构。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103743732","title":"四环医药（00460）公布董事会及四大专门委员会最新成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1103743732","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103743732?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:06","pubTimestamp":1787717162,"startTime":"0","endTime":"0","summary":"四环医药控股集团有限公司8月26日发布公告，披露公司董事会及下设四大专门委员会的最新成员构成。此次公告未涉及财务数据及经营业绩调整。公告显示，上述名单及任命自2026年8月26日起生效。公司表示，董事会及四大委员会的设立旨在进一步完善公司治理架构，明确职责分工，确保决策过程的规范性与透明度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101194677","title":"四环医药人事变动：苗贵利辞任执行董事、副总经理及首席财务官，8月26日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1101194677","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101194677?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:03","pubTimestamp":1787717017,"startTime":"0","endTime":"0","summary":"四环医药近日发布公告，披露了一项重要的人事调整。公司宣布，苗贵利先生已正式提出辞呈，将卸任其在公司担任的多项关键职务，包括执行董事、副总经理以及首席财务官。据悉，这一变动将自2026年8月26日起正式生效。苗贵利先生的离职涉及多个核心管理岗位，其辞任范围之广，在公司治理层面引起了广泛关注。截至目前，四环医药尚未就接任人选或过渡计划发布进一步说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","00460","BK1191","BK1593","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661473242","title":"医美板块整体承压 时代天使（06699）跌2.53%、四环医药（00460）跌2.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661473242","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661473242?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:33","pubTimestamp":1787538824,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医美板块整体承压，截至发稿，昊海生物科技 跌5.16%，时代天使跌2.53%，复星医药跌2.30%，四环医药跌2.29%，山东新华制药股份跌1.37%，现代牙科跌1.22%。华龙证券新近研究指，企业层面，国内医美企业持续突破海外监管认证，海外市场有望成为重要增长第二曲线，行业高质量发展态势明确。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NTQxOTRlZTU5ZGZkZjc4MmEzMTdjMTVhMTM1NjYxOTg3NzU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989117","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06699","06826","BK1583","BK1600","00460","BK1100","BK1515","BK1593","03600","BK1587","BK1161","00719","02196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660406619","title":"港股异动 | 四环医药(00460)涨超6% 上半年净利预增不低于217.2% 公司医美业务进入快速放量阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2660406619","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660406619?lang=zh_cn&edition=full","pubTime":"2026-08-20 14:18","pubTimestamp":1787206705,"startTime":"0","endTime":"0","summary":"消息面上，近期，四环医药业绩盈喜预告，集团预期于截至2026年6月30日止六个月取得收入不低于人民币11.4亿元，与去年同期大致持平；取得期内净利润不低于人民币2.1亿元，较去年同期增长不低于217.2%。该行认为，公司医美业务进入快速放量阶段，创新药及其他药品、仿制药业务盈利有望改善，公司经营拐点已至。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482492.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","KCAI","BK1593","BK4588","00460","BK1600","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":-0.0464},{"period":"1month","weight":-0.0769},{"period":"3month","weight":-0.1325},{"period":"6month","weight":-0.4972},{"period":"1year","weight":-0.5041},{"period":"ytd","weight":-0.4074}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0368},{"period":"3month","weight":0.077},{"period":"6month","weight":-0.0258},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家主要从事研发、制造及销售医药产品和医美产品的投资控股公司。该公司通过三个分部运营其业务。医美产品分部包括填充类、塑形类、支撑类、补充类、光电设备类、体雕类、皮肤管理类及其他以及提供轻医美综合解决方案。创新药及其他药品分部从事研发及商业化糖尿病、乳腺癌、消化、肿瘤及非酒精性脂肪型肝炎等疾病领域的创新药。仿制药分部从事包括克林澳等仿制药的生产和销售。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.119713},{"month":2,"riseRate":0.5,"avgChangeRate":0.000651},{"month":3,"riseRate":0.3125,"avgChangeRate":-0.032043},{"month":4,"riseRate":0.533333,"avgChangeRate":0.038601},{"month":5,"riseRate":0.4,"avgChangeRate":0.003084},{"month":6,"riseRate":0.533333,"avgChangeRate":-0.005353},{"month":7,"riseRate":0.6,"avgChangeRate":0.012776},{"month":8,"riseRate":0.466667,"avgChangeRate":-0.024743},{"month":9,"riseRate":0.2,"avgChangeRate":-0.044796},{"month":10,"riseRate":0.571429,"avgChangeRate":0.02973},{"month":11,"riseRate":0.466667,"avgChangeRate":0.008336},{"month":12,"riseRate":0.4,"avgChangeRate":-0.017751}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}